Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Open access

Abstract

The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolites, such as short chain fatty acids (SCFAs), are important regulators of cancer immunity; however, our knowledge on the effects of individual SCFAs remains limited. Here, we show that isobutyric acid has the strongest effect among SCFAs on both immune activity and tumour growth. In vitro, cancer cell numbers were suppressed by approximately 75% in humans and mice compared with those in controls. Oral administration of isobutyric acid to carcinoma-bearing mice enhanced the effect of anti-PD-1 immunotherapy, reducing tumour volume by approximately 80% and 60% compared with those in the control group and anti-PD-1 antibody alone group, respectively. Taken together, these findings may support the development of novel cancer therapies that can improve the response rate to ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-024-59677-1

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preferential inhibition of cancer cell survival by isobutyric acid over that of T cells. (a) Human T cells (5 × 105 cells) and T3M-1 Clone2 oral cancer cells (5 × 104 cells) were co-cultured for 72 h with isobutyric acid at the indicated concentrations. The number of cancer and T cells was analysed by flow cytometry using fluorescent counting beads. CD45-positive cells were defined as T cells and all others as cancer cells. The graphs in the left, centre, and right represent cancer/T cell co-culture, T cell mono-culture, and cancer cell mono-culture, respectively. (b) Mouse T cells and CT-26 cancer cells were co-cultured for 72 h with isobutyric acid at the indicated concentrations. The number of cancer and T cells was analysed using flow cytometry. To examine the effect of acidic conditions, hydrochloric acid was added to induce a low pH as that induced by 10 mM isobutyric acid. Data are representative of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl hydrochloric acid, isoBA isobutyric acid.
Figure 1 Preferential inhibition of cancer cell survival by isobutyric acid over that of T cells. (a) Human T cells (5 × 105 cells) and T3M-1 Clone2 oral cancer cells (5 × 104 cells) were co-cultured for 72 h with isobutyric acid at the indicated concentrations. The number of cancer and T cells was analysed by flow cytometry using fluorescent counting beads. CD45-positive cells were defined as T cells and all others as cancer cells. The graphs in the left, centre, and right represent cancer/T cell co-culture, T cell mono-culture, and cancer cell mono-culture, respectively. (b) Mouse T cells and CT-26 cancer cells were co-cultured for 72 h with isobutyric acid at the indicated concentrations. The number of cancer and T cells was analysed using flow cytometry. To examine the effect of acidic conditions, hydrochloric acid was added to induce a low pH as that induced by 10 mM isobutyric acid. Data are representative of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl hydrochloric acid, isoBA isobutyric acid.CC BY · PubMed Central
Figure 2 Characterisation of T cell populations upon treatment with isobutyric acid. Human or mouse T cells (5 × 105 cells) were co-cultured with T3M-1 Clone2 oral cancer cells or CT-26 cells (5 × 104 cells) respectively in the presence of different concentrations of isobutyric acid for 72 h. Afterwards, the T cell populations were evaluated based on the expression of surface markers using flow cytometry. (a) Percentage of CD4+ T cells, CD8+ T cells, and Treg cells present in the cancer/T cell co-cultures with isobutyric acid. (b–d) Expression of PD-1 (b) and HLA-DR (c) and ICOS (d) in CD4 + T cells, CD8 + T cells, and Treg cells. To examine the effect of acidic condition, hydrochloric acid was added to induce a low pH as that induced by 10 mM isobutyric acid. Data are mean of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl 10 mM hydrochloric acid, isoBA isobutyric acid, ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs NT.
Figure 2 Characterisation of T cell populations upon treatment with isobutyric acid. Human or mouse T cells (5 × 105 cells) were co-cultured with T3M-1 Clone2 oral cancer cells or CT-26 cells (5 × 104 cells) respectively in the presence of different concentrations of isobutyric acid for 72 h. Afterwards, the T cell populations were evaluated based on the expression of surface markers using flow cytometry. (a) Percentage of CD4+ T cells, CD8+ T cells, and Treg cells present in the cancer/T cell co-cultures with isobutyric acid. (b–d) Expression of PD-1 (b) and HLA-DR (c) and ICOS (d) in CD4 + T cells, CD8 + T cells, and Treg cells. To examine the effect of acidic condition, hydrochloric acid was added to induce a low pH as that induced by 10 mM isobutyric acid. Data are mean of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl 10 mM hydrochloric acid, isoBA isobutyric acid, ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs NT.CC BY · PubMed Central
Figure 3 Direct effects of isobutyric acid on gene expression in T cells. Human and mouse T cells were cultured with various concentrations of isobutyric acid for 72 h before RNA extraction. Gene expression of IFNG, ICOS, PDCD1, and FOXP3 in human (a) and mouse (b) T cells was measured using quantitative PCR. Data are presented as relative values against non-treated cells and are mean of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl hydrochloric acid, isoBA isobutyric acid.
Figure 3 Direct effects of isobutyric acid on gene expression in T cells. Human and mouse T cells were cultured with various concentrations of isobutyric acid for 72 h before RNA extraction. Gene expression of IFNG, ICOS, PDCD1, and FOXP3 in human (a) and mouse (b) T cells was measured using quantitative PCR. Data are presented as relative values against non-treated cells and are mean of three independent experiments. Error bars represent S.E.M. NT no treatment, HCl hydrochloric acid, isoBA isobutyric acid.CC BY · PubMed Central
Figure 4 Anti-cancer effect of isobutyric acid in mice treated with an anti-PD-1 antibody. (a) BALB/C mice with CT26 cancers (n = 40) were pre-treated with orally administered 100 mM isobutyric acid or pH-matched water and intraperitoneally injected with 150 μg/150 μL of anti-PD-1 antibody or IgG on days 4, 11, 18, and 25 after cancer cell inoculation. (b) Tumour volume was analysed on day 28 after inoculation of tumour cells. (c) CT26 tumour growth curves. (d) Pictures of removed tumours. Pictures without a tumour on it represent a tumour that has disappeared. (e) Objective response rate (ORR). (f,g) Haematoxylin and eosin (H&E) staining, and CD3 immunostaining of excised cancer tissues. Scale bar 100 μm. (h) IFNG, ICOS, PDCD1, CTLA-4, CD69, and CD95 levels in explanted cancer tissues. Data were obtained from two independent experiments. Statistical analysis was performed using ANOVA with Dunnett’s multiple comparison test. ns not significant. Error bars represent S.E.M.
Figure 4 Anti-cancer effect of isobutyric acid in mice treated with an anti-PD-1 antibody. (a) BALB/C mice with CT26 cancers (n = 40) were pre-treated with orally administered 100 mM isobutyric acid or pH-matched water and intraperitoneally injected with 150 μg/150 μL of anti-PD-1 antibody or IgG on days 4, 11, 18, and 25 after cancer cell inoculation. (b) Tumour volume was analysed on day 28 after inoculation of tumour cells. (c) CT26 tumour growth curves. (d) Pictures of removed tumours. Pictures without a tumour on it represent a tumour that has disappeared. (e) Objective response rate (ORR). (f,g) Haematoxylin and eosin (H&E) staining, and CD3 immunostaining of excised cancer tissues. Scale bar 100 μm. (h) IFNG, ICOS, PDCD1, CTLA-4, CD69, and CD95 levels in explanted cancer tissues. Data were obtained from two independent experiments. Statistical analysis was performed using ANOVA with Dunnett’s multiple comparison test. ns not significant. Error bars represent S.E.M.CC BY · PubMed Central
Figure 5 Overview of the effects of isobutyric acid on cancer and T cells in the tumour microenvironment. Isobutyric acid exerts a direct anti-tumour effect on cancer cells. Isobutyric acid suppresses Tregs, activates effector T cells, and increases the number of T cells expressing PD-1. Isobutyric acid enhances the efficacy of anti-PD-1 immunotherapy through its direct action on cancer cells and activation of T cells.
Figure 5 Overview of the effects of isobutyric acid on cancer and T cells in the tumour microenvironment. Isobutyric acid exerts a direct anti-tumour effect on cancer cells. Isobutyric acid suppresses Tregs, activates effector T cells, and increases the number of T cells expressing PD-1. Isobutyric acid enhances the efficacy of anti-PD-1 immunotherapy through its direct action on cancer cells and activation of T cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 48

Metadata

Authors
Murayama, M., Hosonuma, M., Kuramasu, A., Kobayashi, S., Sasaki, A., Baba, Y., Narikawa, Y., Toyoda, H., Isobe, J., Funayama, E., Tajima, K., Sasaki, A., Maruyama, Y., Yamazaki, Y., Shida, M., Hamada, K., Hirasawa, Y., Tsurui, T., Ariizumi, H., Ishiguro, T., Suzuki, R., Ohkuma, R., Kubota, Y., Horiike, A., Sambe, T., Tsuji, M., Wada, S., Kobayashi, S., Shimane, T., Tsunoda, T., Kobayashi, H., Kiuchi, Y., & Yoshimura, K.
Affiliations
SHOWA Medical University (JP)
Corresponding author
Yoshimura, Kiyoshi
Venue
Scientific Reports
Published
2024-05-17
Volume
14
Issue
1
Pages
11325-11325
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4397022927
Cited by
41
References
29
Citations by year
2026: 14 · 2025: 22 · 2024: 5
FWCI
7.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Grant-in-Aid for Scientific Research (22K09675)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
isobutyric acid, short-chain fatty acids, anti-PD-1, immune checkpoint inhibitors, cancer immunotherapy, gut microbiota, tumor microenvironment, cancer immunotherapy response, oral administration, tumor growth inhibition
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Drug Synergism, Fatty Acids, Volatile, Female, Humans, Immunotherapy, Neoplasms, Cell Line, Tumor, Mice, Isobutyrates, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. https://app.cochat.ai/papers/10.1038/s41598-024-59677-1
The paper
Murayama, M., Hosonuma, M., Kuramasu, A., Kobayashi, S., Sasaki, A., Baba, Y., Narikawa, Y., Toyoda, H., Isobe, J., Funayama, E., Tajima, K., Sasaki, A., Maruyama, Y., Yamazaki, Y., Shida, M., Hamada, K., Hirasawa, Y., Tsurui, T., Ariizumi, H., . . . Yoshimura, K. (2024). Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Scientific Reports. https://doi.org/10.1038/s41598-024-59677-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.